Proficio Capital Partners LLC Buys 144,099 Shares of Moderna, Inc. (NASDAQ:MRNA)

Proficio Capital Partners LLC grew its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4,418.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 147,360 shares of the company’s stock after acquiring an additional 144,099 shares during the period. Proficio Capital Partners LLC’s holdings in Moderna were worth $6,127,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB grew its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in shares of Moderna during the 4th quarter valued at approximately $37,000. Venturi Wealth Management LLC grew its position in shares of Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after acquiring an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares during the period. Finally, Blue Trust Inc. grew its stake in Moderna by 53.1% in the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock valued at $47,000 after buying an additional 388 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 0.9 %

Moderna stock opened at $34.62 on Monday. The company has a market capitalization of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. The firm has a fifty day simple moving average of $35.94 and a two-hundred day simple moving average of $47.15. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research note on Friday, February 14th. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price objective (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $59.60.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.